Development of a New Adult Sickle Cell Disease Center Within an Academic Cancer Center: Impact on Hospital Utilization Patterns and Care Quality

Overview

Journal J Racial Ethn Health Disparities

Specialties Public Health
Social Sciences

Date 2016 Feb 21

PMID 26896118

Citations 4

Authors

Biree Andemariam

Sasia Jones

Affiliations

Soon will be listed here.

Abstract

Background: A national shortage of specialized centers with expertise in the management of adults with sickle cell disease (SCD) remains a concerning public health disparity. Yet, there is an abundance of cancer centers whose operational infrastructure is not only suited to the treatment of the oncology patient, but also can provide medical and procedural care essential to the management of the patient with SCD. Our adult SCD center was formally embedded within an academic hospital-based cancer center in 2009. An evaluation of the impact of this new center has been performed.

Methods: A retrospective chart review was conducted of all SCD encounters occurring 5 years pre- and post-SCD center establishment. Demographic, clinical, as well as hospital utilization and care quality data were compared.

Results: The SCD population grew from 22 to 165 patients. Following establishment of the SCD center, patients experienced greater average annual outpatient preventative visits for chronic disease management (1 vs. 4.1) and fewer average hospitalizations yearly (2.4 vs. 1). There was a decrease in hospitalization rates for management of acute pain (50 vs. 23 %), average hospitalization length of stay (12 vs. 6 days), and the proportion of hospital discharges resulting in readmission within 30 days (60 vs. 40 %). Hydroxyurea use among eligible patients increased from 30 to 90 %.

Conclusion: Findings suggest that embedding adult SCD centers within existing cancer centers can positively impact patterns of health care utilization and improve the quality of care.

Citing Articles

A telemedicine triage model for infusion center-based management of adult sickle cell pain episodes.

Bliamptis J, You A, Groesbeck J, Sacknoff S, Byrne S, Gopal S Blood Adv. 2024; 9(3):603-605.

PMID: 39642319 PMC: 11847071. DOI: 10.1182/bloodadvances.2024013973.

Clinical Delivery and Effectiveness of Music Therapy in Hematology and Oncology: An EMMPIRE Retrospective Study.

Rodgers-Melnick S, Rivard R, Block S, Dusek J Integr Cancer Ther. 2022; 21:15347354221142538.

PMID: 36510393 PMC: 9751180. DOI: 10.1177/15347354221142538.

Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.

Kanter J, Smith W, Desai P, Treadwell M, Andemariam B, Little J Blood Adv. 2020; 4(16):3804-3813.

PMID: 32785684 PMC: 7448595. DOI: 10.1182/bloodadvances.2020001743.

Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program.

Rousseau R, Weisberg D, Gorero J, Parwani V, Bozzo J, Kenyon K PLoS One. 2020; 15(7):e0236360.

PMID: 32706825 PMC: 7380627. DOI: 10.1371/journal.pone.0236360.

Impact of Chronic Conditions on Emergency Department Visits of Children Using Medicaid.

Berry J, Rodean J, Hall M, Alpern E, Aronson P, Freedman S J Pediatr. 2016; 182:267-274.

PMID: 27979584 PMC: 7398048. DOI: 10.1016/j.jpeds.2016.11.054.

References

Menis M, Burwen D, Holness L, Anderson S . Blood use in the ambulatory setting among elderly in the United States. Transfusion. 2009; 49(6):1186-94. DOI: 10.1111/j.1537-2995.2009.02114.x. View

Laurin L, Nachman P, Desai P, Ataga K, Derebail V . Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dial Transplant. 2013; 29(6):1211-8. PMC: 4038249. DOI: 10.1093/ndt/gft295. View

Steinberg M, Mccarthy W, Castro O, Ballas S, Armstrong F, Smith W . The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010; 85(6):403-8. PMC: 2879711. DOI: 10.1002/ajh.21699. View

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K . Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014; 38(5):557-63. DOI: 10.1016/j.leukres.2014.02.003. View

Downes S, Hambleton I, Chuang E, Lois N, Serjeant G, Bird A . Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology. 2005; 112(11):1869-75. DOI: 10.1016/j.ophtha.2005.05.026. View

Yawn B, Buchanan G, Afenyi-Annan A, Ballas S, Hassell K, James A . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10):1033-48. DOI: 10.1001/jama.2014.10517. View

Ballas S, Vichinsky E . Is the medical home for adult patients with sickle cell disease a reality or an illusion?. Hemoglobin. 2015; 39(2):130-3. DOI: 10.3109/03630269.2015.1023312. View

Christoforidou A, Pantelidou D, Anastasiadis A, Goutzouvelidis A, Margaritis D, Kotsianidis I . Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta Haematol. 2009; 120(4):195-8. DOI: 10.1159/000189381. View

Brawley O, Cornelius L, Edwards L, Gamble V, Green B, Inturrisi C . National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008; 148(12):932-8. DOI: 10.7326/0003-4819-148-12-200806170-00220. View

10.

Artz N, Whelan C, Feehan S . Caring for the adult with sickle cell disease: results of a multidisciplinary pilot program. J Natl Med Assoc. 2010; 102(11):1009-16. DOI: 10.1016/s0027-9684(15)30727-6. View

11.

Wright J, Bareford D, Wright C, Augustine G, Olley K, Musamadi L . Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol. 2004; 126(6):878-80. DOI: 10.1111/j.1365-2141.2004.05123.x. View

12.

CHARACHE S, Terrin M, Moore R, Dover G, Barton F, Eckert S . Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995; 332(20):1317-22. DOI: 10.1056/NEJM199505183322001. View

13.

Lanzkron S, Haywood Jr C, Hassell K, Rand C . Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008; 100(8):968-73. View

14.

Fox P, Vessey S, Forshaw M, Serjeant G . Influence of genotype on the natural history of untreated proliferative sickle retinopathy--an angiographic study. Br J Ophthalmol. 1991; 75(4):229-31. PMC: 1042329. DOI: 10.1136/bjo.75.4.229. View

15.

Works T, Jones S, Grady J, Andemariam B . Traumatic Exposure History as a Risk Factor for Chronic Pain in Adult Patients with Sickle Cell Disease. Health Soc Work. 2016; 41(1):42-50. DOI: 10.1093/hsw/hlv085. View

16.

Smith L, Oyeku S, Homer C, Zuckerman B . Sickle cell disease: a question of equity and quality. Pediatrics. 2006; 117(5):1763-70. DOI: 10.1542/peds.2005-1611. View

17.

Hankins J, Helton K, McCarville M, Li C, Wang W, Ware R . Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer. 2007; 50(2):293-7. DOI: 10.1002/pbc.21271. View

18.

Andemariam B, Owarish-Gross J, Grady J, Boruchov D, Thrall R, Hagstrom J . Identification of risk factors for an unsuccessful transition from pediatric to adult sickle cell disease care. Pediatr Blood Cancer. 2013; 61(4):697-701. DOI: 10.1002/pbc.24870. View

19.

Belini Junior E, Silva D, de Souza Torres L, Okumura J, de Castro Lobo C, Bonini-Domingos C . Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use. Blood Cells Mol Dis. 2015; 54(4):321-7. DOI: 10.1016/j.bcmd.2015.01.011. View

20.

Benjamin L, Swinson G, Nagel R . Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000; 95(4):1130-6. View